Key result
LDLR disruption improves chemotherapy efficacy in pancreatic ductal adenocarcinoma via intratumoral cholesterol imbalance.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
The role of altered lipid metabolism in pancreatic ductal adenocarcinoma (PDAC) is poorly appreciated. We recently identified the lipid signature of PDAC and revealed low-density lipoprotein receptor (Ldlr) as a metabolic driver of this disease. Here, we comment our findings that disruption of Ldlr leads to intratumoral cholesterol imbalance and improves chemotherapy efficiency.
No takes yet. Share an insight, caveat, or question.
Vasseur et al. (2015) studied this question. Low-density lipoprotein receptor disruption induces intratumoral cholesterol imbalance and improves chemotherapy efficiency in pancreatic ductal adenocarcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: